⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11700733 | 0.80 | — | — | |
| SCHEMBL21611492 | 0.74 | — | — | |
| SCHEMBL4075559 | 0.74 | — | — | |
| SCHEMBL151026 | 0.69 | — | — | |
| SCHEMBL29972199 | 0.69 | — | — | |
| SCHEMBL8560673 | 0.69 | JAK3 (0.34) | — | |
| SCHEMBL2520189 | 0.69 | — | — | |
| SCHEMBL11731053 | 0.69 | NOS2 (0.46) | — | |
| SCHEMBL5007782 | 0.68 | — | — | |
| SCHEMBL5679719 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139593-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS AND COMPOUNDS FOR SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-04 | — | — | US | disclosed |
| EP-4118066-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS AND COMPOUNDS FOR SAME | The University of Adelaide (AU) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021179049-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS AND COMPOUNDS FOR SAME | THE UNIVERSITY OF ADELAIDE (AU) | 2021-09-16 | — | — | WO | disclosed |
| EP-3853216-A1 | SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF | Bionomics Limited (AU) | 2021-07-28 | — | — | EP | disclosed |
| US-20200392126-A1 | ISOXAZOLYL COMPOUNDS AS RECEPTOR MODULATING COMPOUNDS AND METHODS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-12-17 | — | — | US | disclosed |
| WO-2019222816-A1 | SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2019-11-28 | — | — | WO | disclosed |
| WO-2019109132-A1 | ISOXAZOLYL COMPOUNDS AS RECEPTOR MODULATING COMPOUNDS AND METHODS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2019-06-13 | — | — | WO | disclosed |
| WO-2018102885-A1 | MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2018-06-14 | — | — | WO | disclosed |
| US-8759365-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| EP-2404901-A1 | 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | Novartis AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2229356-B1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-20100311750-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-2229356-A1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | Novartis AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100234390-A1 | NOVEL COMPOUND AND THEIR USE | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-16 | — | — | US | disclosed |
| WO-2009071509-A1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| WO-2006038001-A1 | AMINOPYRIMIDINE DERIVATIVES AS JNK INHIBITORS | CELLTECH R & D LIMITED (GB) | 2006-04-13 | — | — | WO | disclosed |